Tag Archives: finance

Super Early Bird Rates End October 3 for RESI London and RESI JPM 

30 Sep

By Sougato Das, President and COO, LSN

Sougato-Das

Life Science Nation’s Redefining Every Stage of Investments (RESI) conferences are designed to connect life science companies with global investors and strategic partners. Two major upcoming events, RESI London and RESI JPM, are now open for registration at Super Early Bird rates through October 3. By registering early, attendees can save £300 on RESI London and $800 on RESI JPM.

RESI London 2025

The first week of December marks the largest life science partnering and venture week in the UK. If you are raising pre-seed, seed, round A or round B, or are in phase 2 or earlier development, Life Science Nation’s RESI London, One Nucleus’ Genesis, and ELRIG/SLAS events offer stronger partnering, investment, learning, and procurement opportunities compared to the health care week in late November that runs alongside the Jefferies investment banking event. That November week typically focuses on recent IPOs, companies close to IPO, and phase 3 or more advanced companies seeking partnerships. For companies not yet at that stage, December’s conference series is a more strategic use of critical conference and travel budgets.

RESI London and Genesis are joining to provide a multi-day investment, partnering, and thought leadership event for venture-stage companies pursuing funding and strategic alliances. RESI London will take place on December 4 at 1 Wimpole Street and 11 Cavendish Square, followed by two days of virtual partnering on December 5 and 6. Super Early Bird registration is now open, offering a savings of £300 until October 3.

RESI JPM 2026

RESI JPM will be held January 12–13, 2026, at the San Francisco Marriott Marquis. The program features two days of in-person investor panels, workshops, networking, and one-on-one partnering, followed by three days of online partnering on January 14, 19, and 20.

Previous RESI JPM conferences have drawn more than one thousand attendees, including over 500 investors, innovators, and industry experts from across the globe. The conference is held concurrently with JP Morgan Healthcare Week, January 12–15, 2026, which takes place at the Westin St. Francis. Known as the largest healthcare investment symposium worldwide, JPM attracts thousands of life science professionals each year.

Super Early Bird registration for RESI JPM offers a savings of $800 when completed before October 3.

Register for RESI London
Register for RESI & Genesis Combi Ticket		 Register for RESI JPM

Both conferences provide access to global investors and in-licensors, strategic partners, and hundreds of early-stage innovators across therapeutics, medical devices, diagnostics, and digital health. Register now to take advantage of Super Early Bird discounts for RESI London and RESI JPM before October 3.

Tags: , , , , , , , , , , , , , , , ,

Investor Panels at RESI JPM 2026 

30 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is excited to announce the lineup of investor panels at RESI JPM 2026, taking place January 12–13. These panels bring together leading venture capitalists, corporate investors, and strategic partners to discuss the latest trends, challenges, and opportunities in life science investing. From early-stage “first check” VCs to specialized sectors like Cell & Gene Therapy, AI in Healthcare, and Longevity, RESI JPM offers unparalleled insight into the funding landscape. 

Day 1 – January 12 

  • 9:00 AM | “First Check” VCs Panel: Learn how early-stage investors evaluate founders, milestones, and the critical first institutional check. 
  • 10:00 AM | Medtech Strategics Panel: Explore how strategic investors from leading medtech companies drive growth through partnerships and acquisitions. 
  • 11:00 AM | Asia Cross Border Investments Panel: Sponsored by Enterprise Singapore, a RESI JPM Title Sponsor
  • 1:00 PM | Family Offices Panel: Hear how family offices provide patient, mission-driven capital to early- and growth-stage companies. 
  • 2:00 PM | Cell & Gene Therapy Panel: Discover where capital is flowing in this transformative area of medicine. 
  • 3:00 PM | When Should Companies Exit Stealth Mode?: Gain insight into timing the transition from quiet development to public visibility. 
  • 4:00 PM | Aging and Longevity Panel: Learn how investors are deploying capital to solutions addressing the world’s aging population. 

Day 2 – January 13 

  • 9:00 AM | Partnering with Global Pharma Panel: Understand how big pharma approaches early-stage partnerships and collaboration. 
  • 10:00 AM | Women’s Health Panel: Explore investment opportunities in an underserved market with enormous potential. 
  • 11:00 AM | AI in Healthcare: Discover how AI is reshaping drug development and care delivery. 
  • 1:00 PM | Orphan & Rare Diseases Panel: Learn about unique challenges and opportunities in niche, high-need markets. 
  • 2:00 PM | Corporate VC Panel: Hear how corporate venture capital balances strategic and financial goals to accelerate innovation. 
  • 3:00 PM | Techbio & Synthetic Biology Panel: Explore investment trends at the intersection of biology and technology. 
  • 4:00 PM | 2026 Outlook: VC Perspectives Panel: Gain insight into where investors see healthcare innovation heading in the coming year. 

These panels are designed not only to share insights but also to foster dialogue between investors and innovators. If you are interested in speaking on a RESI JPM investor panel, please reach out here. 

Registration for RESI JPM 2026 is now open, with Early Bird rates available until October 24. Don’t miss your chance to connect with top investors, strategic partners, and fellow innovators at one of the premier life science partnering events. Register for RESI JPM 2026 

Register for RESI JPM >>

Tags: , , , , , , , , , ,

Hot Investor Mandate: USA-Based Early Stage Fund Invests in Medical Devices, Diagnostics, Digital Health Companies in Underserved Regions

30 Sep

 The firm is an early-stage life sciences focused venture capital investor. The firm targets Series A investment rounds but considers later stage investments and plans to make follow-on commitments throughout a company’s life cycle. Typical initial check sizes can range from $1M to $2.5M. The firm may lead or co-invest on a case-by-case basis and often syndicates with other strong life science investors. The firm invests across the United States, with a focus on underserved or underrepresented regions. 
 
The firm is interested in medical devices, diagnostics, digital health, and medical instruments. The firm does not invest in traditional drug assets but may consider peripheral areas such as drug delivery or platform technologies. For medical devices, the firm primarily considers products with B2B models and a clear FDA regulatory pathway. The firm is opportunistic in terms of indications/disease areas. For development stage, the firm prefers companies with products or assets that are within 18 months of commercialization and have a well-defined regulatory pathway. 
 

There is no specific requirement for companies and the management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Impact Fund Seeks Early-Stage Companies Across Europe, Investing in All Life Science and Healthcare Sectors 

30 Sep

 An impact venture investor focuses on healthcare and climate, with specialized teams for each vertical. With its current fund, the firm is allocating €1M for initial checks with flexibility to make follow-on investments. The firm invests in Seed rounds but can enter earlier or later. The firm’s investments are focused in Europe.  
 

In healthcare, the firm is technology agnostic and invests in solutions that help improve the quality of life for vulnerable populations: the elderly, people with chronic diseases, and people with mental or physical disabilities. For digital health companies, the firm seeks to see product-market fit. 

The firm can act as a lead investor and join syndicates. The firm requests to take a board seat, as it prefers to be an active investor. The firm would like to see committed and diverse management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Life Sciences Focused Fund With Global Reach Invests in Therapeutics and Medtech Companies Based in North America, Europe, and Parts of Asia

30 Sep

A life sciences-focused venture capital investor based in the US is actively seeking new investment opportunities. In addition, the firm recently closed on a new fund through its specialized funds business unit that invests in companies in Asia. The firm generally supports companies with lead assets that can reach high-value inflection points in 3–4 years and will consider opportunities in the U.S., Canada, Europe, Singapore, Hong Kong, and China. 

The firm is currently seeking companies developing therapeutics or medical technologies to treat true unmet medical needs. It is therapeutic area agnostic, though it has historically been most active in immunology, oncology, and rare diseases. The firm typically prefers to invest in Series A/B rounds with a preference for lead assets between 18 months pre-IND and Phase 2a. Within devices, the firm generally prefers later-stage opportunities, particularly those that have received market approval with early revenue. 

The firm does not have any specific requirements for management teams. It is an active investor and seeks a director or observer position on portfolio company boards. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: US-Based Single Family Office Invests in Breakthrough Therapeutics, Medical Devices, and Diagnostics in North America

30 Sep

 A single-family office with U.S.-based family interests. While the firm is very flexible in terms of investment size, it generally looks to invest a minimum of $0.5M per round, depending on the round size and estimated capital call. The firm prefers Series A and later-stage companies, with Pre-A interest depending on technology stage. Currently, the firm invests only in companies based in North America.  

The firm is looking for breakthrough technologies with a strong social ethos in the therapeutics, medical devices, and diagnostics sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. Areas of particular interest include optical or sound-based technologies, devices that supplant drug use, orthopedics, gene/nucleic acid-based therapies, immuno-oncology, and therapies correcting or treating loss of senses. 

The firm is currently reviewing co-investment opportunities in private companies and, on an opportunistic basis, considering investments in micro- and small-cap public companies as a direct investor. The firm prefers companies that have already raised seed financing and have received allowance of claims by the USPTO. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

RESI Boston September 2025 Innovator’s Pitch Challenge Winners 

23 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

At RESI Boston September 2025, over 50 innovative companies participated in the Innovator’s Pitch Challenge (IPC), providing early-stage life science and healthcare companies with a unique platform to present their technologies and connect with potential investors.

The IPC finalists delivered 6-minute pitches followed by a 7-minute interactive Q&A session with a panel of investor judges. Each participating company also showcased its technology at a personalized table space in the RESI Exhibition Hall, creating additional opportunities for engagement.

A distinctive feature of the Innovator’s Pitch Challenge is its voting system. Registered RESI attendees—including startup executives, early-stage investors, and industry experts— “invested” in their favorite IPC companies using RESI cash provided at check-in. Attendees base their decisions on both the pitch presentations, the companies’ responses during Q&A, meeting with them in the exhibition hall at their table space, and during partnering or ad-hoc meetings at RESI.

Applications are now open for the next Innovator’s Pitch Challenge at RESI London 2025 and RESI JPM 2026, with spots filled on a rolling basis.

Life Science Nation is proud to announce the top three winners of RESI Boston September 2025:

1st Place: Isotech

IsoTech Ltd is developing a novel wearable therapeutic medical device that stabilises blood pressure on standing to help older adults avoid dizziness and falls from orthostatic hypotension. The device guides a 30–60-second, on-demand isometric muscle contraction via a discreet retractable tether with visual and haptic cues, turning an evidence-based counter-manoeuvre into a simple, repeatable action without drug side effects. A completed proof-of-concept clinical study demonstrated clinically meaningful blood-pressure stabilisation in a substantial subset of patients with high usability and no unwanted adverse effects. The next phase is straightforward but execution-critical: design-for-manufacture and verification, Class I UKCA/CE technical documentation and light-touch QMS, tooling and pilot build, and a KOL-led seeded launch while preparing reimbursement pilots and strategic licensing options. Protected by patents on mechanism and form factor, ISO-101 aims to become the category-defining, real-time therapy for OH, improving independence for ageing populations and reducing falls-related costs for health systems at scale.

Dr Lochlainn Connolly, Founder – EVP Medical Affairs, Isotech | Dr Neil Fawkes, Founder / EVP R&D, Isotech | Dennis Ford, Founder and CEO, Life Science Nation | Iggy McGowan, Founder / CEO, Isotech

2nd Place: BILIX

Bilix, founded in Oct 2018, raised $21 million in investments and received $3 million in government grants to develop a new drug for various inflammatory and autoimmune diseases. Our first target is ischemia-reperfusion injury, where unmet medical needs are high and no drugs. Global companies (Novartis, Roche, AstraZeneca, Argenx) are in Phase 2 or 3 trials with single-modality drugs (likely to fail). Our Phase 2a clinical trial (our drug being multi-modality, likely to succeed) runs from 2025.09 to 2026.08. We generate royalty revenue from Classys (a $3B market cap laser medical device company) through exclusive LO in cosmeceutical products. We are currently raising Series B-3 of $6M, of which $ 3 M has been secured. With $25.7 million pre-money valuation, an ROI of >10 times is achievable within three years through IPO/M&A. We can flip to a US company with vetted Series C investments from US/Foreign VCs.

Dennis Ford, Founder and CEO, Life Science Nation | Myung L. Kim, Ph.D., MBA, Founder and Chief Executive Officer, Bilix | Claire Jeong, CCO, VP of Investor Research, Asia BD, Life Science Nation

3rd Place: M6P Therapeutics

M6P Therapeutics focuses on lysosomes (the natural recycling center for cells) and has the only technology that can deliver any protein to lysosomes – a feat deemed impossible for over 50 years. The company has a deep pipeline, 6 rare pediatric drug designations, and an IP portfolio comprised of 9 patent families, 8 issued patents, and 20 in progress. Our Gaucher Disease ERT is ready for the clinic and our Pompe Disease ERT – which can restore and normalize muscle function – will be ready in 18 months. We also created a platform that can take any antigen-antibody complex to the lysosomes of any cell in the body (instead of relying on Fc clearance by select immune cells) for degradation. Our “chimeric” anti-PD-L1 antibody removes virtually all PD-L1 from the surface of tumor cells while our chimeric version of Keytruda is twice as potent.

Cole Van Vuren, Business Development Manager, Life Science Nation

The participating companies were grouped into 14 sector-focused sessions, with four companies per session. Each session was evaluated by a panel of judges, and the top-scoring companies were recognized for their strong pitches, ability to answer questions effectively, and clear communication of their value propositions.

Judges Picks:

Tags: , , , , , , , , , ,

← Older Entries
Newer Entries →